vs
PARK NATIONAL CORP（PRK）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
PARK NATIONAL CORP的季度营收约是再鼎医药的1.3倍（$168.3M vs $127.1M），再鼎医药同比增速更快（17.1% vs 2.2%），PARK NATIONAL CORP自由现金流更多（$191.9M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 4.9%）
国家零售系统公司（NRS）旗下包含基石货运公司与国家零售运输公司，是一家成立于1952年的资产型第三方物流服务商，总部位于美国新泽西州林德赫斯特，为客户提供专业的物流供应链相关解决方案。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
PRK vs ZLAB — 直观对比
营收规模更大
PRK
是对方的1.3倍
$127.1M
营收增速更快
ZLAB
高出14.9%
2.2%
自由现金流更多
PRK
多$218.6M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
4.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.3M | $127.1M |
| 净利润 | $42.6M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | — | -54.6% |
| 净利率 | 25.3% | — |
| 营收同比 | 2.2% | 17.1% |
| 净利润同比 | 10.4% | — |
| 每股收益（稀释后） | $2.62 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRKZLAB
| Q4 25 | $168.3M | $127.1M | ||
| Q3 25 | $169.5M | $115.4M | ||
| Q2 25 | $168.7M | $109.1M | ||
| Q1 25 | $157.9M | $105.7M | ||
| Q4 24 | $164.7M | $108.5M | ||
| Q3 24 | $170.3M | $101.8M | ||
| Q2 24 | $157.7M | $100.1M | ||
| Q1 24 | $152.8M | $87.1M |
净利润PRKZLAB
| Q4 25 | $42.6M | — | ||
| Q3 25 | $47.2M | $-36.0M | ||
| Q2 25 | $48.1M | $-40.7M | ||
| Q1 25 | $42.2M | $-48.4M | ||
| Q4 24 | $38.6M | — | ||
| Q3 24 | $38.2M | $-41.7M | ||
| Q2 24 | $39.4M | $-80.3M | ||
| Q1 24 | $35.2M | $-53.5M |
毛利率PRKZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率PRKZLAB
| Q4 25 | — | -54.6% | ||
| Q3 25 | 34.3% | -42.3% | ||
| Q2 25 | 35.2% | -50.3% | ||
| Q1 25 | 32.4% | -53.3% | ||
| Q4 24 | — | -62.6% | ||
| Q3 24 | 27.4% | -66.6% | ||
| Q2 24 | 30.6% | -76.0% | ||
| Q1 24 | 27.8% | -80.7% |
净利率PRKZLAB
| Q4 25 | 25.3% | — | ||
| Q3 25 | 27.8% | -31.2% | ||
| Q2 25 | 28.5% | -37.3% | ||
| Q1 25 | 26.7% | -45.8% | ||
| Q4 24 | 23.5% | — | ||
| Q3 24 | 22.4% | -40.9% | ||
| Q2 24 | 25.0% | -80.2% | ||
| Q1 24 | 23.0% | -61.4% |
每股收益（稀释后）PRKZLAB
| Q4 25 | $2.62 | $-0.05 | ||
| Q3 25 | $2.92 | $-0.03 | ||
| Q2 25 | $2.97 | $-0.04 | ||
| Q1 25 | $2.60 | $-0.04 | ||
| Q4 24 | $2.38 | $-0.09 | ||
| Q3 24 | $2.35 | $-0.04 | ||
| Q2 24 | $2.42 | $-0.08 | ||
| Q1 24 | $2.17 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $233.5M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.4B | $715.5M |
| 总资产 | $9.8B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PRKZLAB
| Q4 25 | $233.5M | $689.6M | ||
| Q3 25 | $218.9M | $717.2M | ||
| Q2 25 | $193.1M | $732.2M | ||
| Q1 25 | $237.6M | $757.3M | ||
| Q4 24 | $160.6M | $779.7M | ||
| Q3 24 | $201.7M | $616.1M | ||
| Q2 24 | $261.5M | $630.0M | ||
| Q1 24 | $306.1M | $650.8M |
股东权益PRKZLAB
| Q4 25 | $1.4B | $715.5M | ||
| Q3 25 | $1.3B | $759.9M | ||
| Q2 25 | $1.3B | $791.7M | ||
| Q1 25 | $1.3B | $810.8M | ||
| Q4 24 | $1.2B | $840.9M | ||
| Q3 24 | $1.2B | $667.7M | ||
| Q2 24 | $1.2B | $704.2M | ||
| Q1 24 | $1.2B | $762.2M |
总资产PRKZLAB
| Q4 25 | $9.8B | $1.2B | ||
| Q3 25 | $9.9B | $1.2B | ||
| Q2 25 | $9.9B | $1.2B | ||
| Q1 25 | $9.9B | $1.2B | ||
| Q4 24 | $9.8B | $1.2B | ||
| Q3 24 | $9.9B | $985.3M | ||
| Q2 24 | $9.9B | $987.4M | ||
| Q1 24 | $9.9B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $198.3M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $191.9M | $-26.7M |
| 自由现金流率自由现金流/营收 | 114.1% | -21.0% |
| 资本支出强度资本支出/营收 | 3.8% | 0.5% |
| 现金转化率经营现金流/净利润 | 4.65× | — |
| 过去12个月自由现金流最近4个季度 | $328.2M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流PRKZLAB
| Q4 25 | $198.3M | $-26.0M | ||
| Q3 25 | $52.6M | $-32.0M | ||
| Q2 25 | $49.7M | $-31.0M | ||
| Q1 25 | $37.9M | $-61.7M | ||
| Q4 24 | $178.8M | $-55.8M | ||
| Q3 24 | $43.8M | $-26.8M | ||
| Q2 24 | $50.9M | $-42.2M | ||
| Q1 24 | $35.0M | $-90.1M |
自由现金流PRKZLAB
| Q4 25 | $191.9M | $-26.7M | ||
| Q3 25 | $51.1M | $-35.0M | ||
| Q2 25 | $48.4M | $-33.9M | ||
| Q1 25 | $36.8M | $-63.2M | ||
| Q4 24 | $169.7M | $-58.4M | ||
| Q3 24 | $41.7M | $-28.2M | ||
| Q2 24 | $49.0M | $-42.9M | ||
| Q1 24 | $31.9M | $-91.1M |
自由现金流率PRKZLAB
| Q4 25 | 114.1% | -21.0% | ||
| Q3 25 | 30.1% | -30.4% | ||
| Q2 25 | 28.7% | -31.1% | ||
| Q1 25 | 23.3% | -59.9% | ||
| Q4 24 | 103.0% | -53.8% | ||
| Q3 24 | 24.5% | -27.7% | ||
| Q2 24 | 31.1% | -42.9% | ||
| Q1 24 | 20.8% | -104.5% |
资本支出强度PRKZLAB
| Q4 25 | 3.8% | 0.5% | ||
| Q3 25 | 0.9% | 2.6% | ||
| Q2 25 | 0.8% | 2.6% | ||
| Q1 25 | 0.7% | 1.5% | ||
| Q4 24 | 5.6% | 2.4% | ||
| Q3 24 | 1.2% | 1.3% | ||
| Q2 24 | 1.2% | 0.7% | ||
| Q1 24 | 2.1% | 1.1% |
现金转化率PRKZLAB
| Q4 25 | 4.65× | — | ||
| Q3 25 | 1.11× | — | ||
| Q2 25 | 1.03× | — | ||
| Q1 25 | 0.90× | — | ||
| Q4 24 | 4.63× | — | ||
| Q3 24 | 1.14× | — | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | 0.99× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRK
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
